RT Journal Article
SR Electronic
T1 Psoriasis assessment tools in clinical trials
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP ii65
OP ii68
DO 10.1136/ard.2004.031237
VO 64
IS suppl 2
A1 Feldman, S R
A1 Krueger, G G
YR 2005
UL http://ard.bmj.com/content/64/suppl_2/ii65.abstract
AB In clinical practice, broad global assessments of psoriasis disease activity and its effect on patients’ quality of life are used to assess the severity of patients’ disease and their response to treatment. In clinical trials, more objective, validated instruments are required. Several such instruments have been developed and continue to be developed to provide an assessment of the severity of the skin lesions. Because a lesion’s impact on patients’ lives varies widely among patients, there has been growing recognition of the need to measure the quality of life impact of the disease along with the severity of the lesions.